Though HER2 (ERBB2) exon 20 insertion mutations occur in ~2% of non-small-cell lung cancers, molecular targeted therapies for such cancers have been lacking. A study now identifies selective HER2 inhibitors that have marked efficacy against tumors driven by HER2 exon 20 insertions, without inhibiting wild-type EGFR activity.
This is a preview of subscription content, log in via an institution to check access.
References
Moasser, M. M. Oncogene 26, 6469–6487 (2007).
Owens, M. A., Horten, B. C. & Da Silva, M. M. Clin. Breast Cancer 5, 63–69 (2004).
Nathanson, D. R. et al. Intl J. Cancer 105, 796–802 (2003).
Stephens, P. et al. Nature 431, 525–526 (2004).
Slamon, D. J. et al. N. Engl. J. Med. 344, 783–792 (2001).
De Greve, J. et al. Lung Cancer 76, 123–127 (2012).
Gandhi, L. et al. J. Clin. Oncol. 32, 68–75 (2014).
Kris, M. G. et al. Ann. Onco.l 26, 1421–1427 (2015).
Elamin, Y. Y. et al. J. Clin. Oncol. 40, 702–709 (2022).
Wilding, B. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00XXX-X (2022).
Tsurutani, J. et al. Cancer Discov. 10, 688–701 (2020).
Verma, S. et al. N. Engl. J. Med. 367, 1783–1791 (2012).
Li, B. T. et al. N. Engl. J. Med. 386, 241–251 (2022).
Modi, S. et al. N. Engl. J. Med. 382, 610–621 (2020).
Shitara, K. et al. N. Engl. J. Med. 382, 2419–2430 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R. Katayama received research funding from Chugai, Toppan Printing, TAKEDA and Daiichi-Sankyo outside the scope of the submitted work.
Rights and permissions
About this article
Cite this article
Katayama, R. Hitting the target in HER2 mutant cancers. Nat Cancer 3, 785–786 (2022). https://doi.org/10.1038/s43018-022-00386-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00386-x
- Springer Nature America, Inc.